Candriam SCA’s ADC Therapeutics ADCT Stock Holding History

Candriam SCA’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8	Closed	–	–	885
2021 Q1	$0	Sell	8 -1	-11%	-$29	﹤0.01%	807
2020 Q4	$0	Buy	+9	New	+$295	﹤0.01%	808

Other funds holding ADCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Candriam SCA's ADCT Position: Q2 2021 in Review

Candriam SCA sold out of ADC Therapeutics (ADCT) in Q2 2021, closing a stake of 8 shares.

Candriam SCA first reported a position in ADCT in Q4 2020 and held it in 2 quarters. The position peaked at $0 in Q1 2021. 56 funds tracked by Wall St. Rank hold ADCT as of Q2 2021.

Candriam SCA reported no remaining ADC Therapeutics position as of Q2 2021 after selling out during the quarter.
Candriam SCA sold 8 ADC Therapeutics shares in Q2 2021.
Candriam SCA first reported a position in ADC Therapeutics in Q4 2020 and held it in 2 quarters.
Candriam SCA's ADC Therapeutics position peaked at $0 in Q1 2021.
56 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2021.

Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.